Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial
- PMID: 31494820
- DOI: 10.1007/s10072-019-04053-5
Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial
Erratum in
-
Correction to: Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial.Neurol Sci. 2020 Mar;41(3):733. doi: 10.1007/s10072-019-04149-y. Neurol Sci. 2020. PMID: 31909448
Abstract
Objective: To evaluate the safety and efficacy of Cerebrolysin as an add-on therapy to local standard treatment protocol in patients after moderate-to-severe traumatic brain injury.
Methods: The patients received the study medication in addition to standard care (50 mL of Cerebrolysin or physiological saline solution daily for 10 days, followed by two additional treatment cycles with 10 mL daily for 10 days) in a prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-centre phase IIIb/IV trial. The primary endpoint was a multidimensional ensemble of 14 outcome scales pooled to be analyzed by means of the multivariate, correlation-sensitive Wei-Lachin procedure.
Results: In 46 enrolled TBI patients (Cerebrolysin 22, placebo 24), three single outcomes showed stand-alone statistically significant superiority of Cerebrolysin [Stroop Word/Dots Interference (p = 0.0415, Mann-Whitney(MW) = 0.6816, 95% CI 0.51-0.86); Color Trails Tests 1 and 2 (p = 0.0223/0.0170, MW = 0.72/0.73, 95% CI 0.53-0.90/0.54-0.91), both effect sizes lying above the benchmark for "large" superiority (MW > 0.71)]. While for the primary multivariate ensemble, statistical significance was just missed in the intention-to-treat population (pWei-Lachin < 0.1, MWcombined = 0.63, 95% CI 0.48-0.77, derived standardized mean difference (SMD) 0.45, 95% CI -0.07 to 1.04, derived OR 2.1, 95% CI 0.89-5.95), the per-protocol analysis showed a statistical significant superiority of Cerebrolysin (pWei-Lachin = 0.0240, MWcombined = 0.69, 95% CI 0.53 to 0.85, derived SMD 0.69, 95% CI 0.09 to 1.47, derived OR 3.2, 95% CI 1.16 to 12.8), with effect sizes of six single outcomes lying above the benchmark for "large" superiority. Safety aspects were comparable to placebo.
Conclusion: Our trial suggests beneficial effects of Cerebrolysin on outcome after TBI. Results should be confirmed by a larger RCT with a comparable multidimensional approach.
Keywords: Cerebrolysin; Multidimensional approach; Traumatic brain injury; Wei-Lachin pooling.
Similar articles
-
Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.Neurol Sci. 2020 May;41(5):1171-1181. doi: 10.1007/s10072-019-04181-y. Epub 2020 Jan 2. Neurol Sci. 2020. PMID: 31897941 Clinical Trial.
-
Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.Neurol Sci. 2021 Nov;42(11):4531-4541. doi: 10.1007/s10072-020-04974-6. Epub 2021 Feb 23. Neurol Sci. 2021. PMID: 33620612
-
Cerebrolysin Asian Pacific trial in acute brain injury and neurorecovery: design and methods.J Neurotrauma. 2015 Apr 15;32(8):571-80. doi: 10.1089/neu.2014.3558. Epub 2015 Jan 28. J Neurotrauma. 2015. PMID: 25222349 Clinical Trial.
-
Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.Biomed Res Int. 2017;2017:4191670. doi: 10.1155/2017/4191670. Epub 2017 Jun 5. Biomed Res Int. 2017. PMID: 28656143 Free PMC article. Review.
-
Cerebrolysin: a multi-target drug for recovery after stroke.Expert Rev Neurother. 2018 Aug;18(8):681-687. doi: 10.1080/14737175.2018.1500459. Epub 2018 Jul 18. Expert Rev Neurother. 2018. PMID: 30004268 Review.
Cited by
-
A multimodal pharmacological agent in combination with recanalization therapy (thrombolysis and thrombectomy) in severe stroke patients.J Med Life. 2019 Oct-Dec;12(4):466-467. doi: 10.25122/jml-2019-1011. J Med Life. 2019. PMID: 32025269 Free PMC article.
-
A Case Report on the Use of Pharmacological Intervention in the Treatment of Diffuse Axonal Injury From Road Traffic Accidents.J Med Life. 2019 Oct-Dec;12(4):468-470. doi: 10.25122/jml-2019-1012. J Med Life. 2019. PMID: 32025270 Free PMC article.
-
Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study.Healthcare (Basel). 2023 May 21;11(10):1497. doi: 10.3390/healthcare11101497. Healthcare (Basel). 2023. PMID: 37239783 Free PMC article.
-
Neuroprotective and neuroregenerative drugs after severe traumatic brain injury : A narrative review from a clinical perspective.Wien Klin Wochenschr. 2024 Dec;136(23-24):662-673. doi: 10.1007/s00508-024-02367-9. Epub 2024 May 15. Wien Klin Wochenschr. 2024. PMID: 38748062 Review.
-
Cyclosporine A Accelerates Neurorecovery Transcriptional Trajectory in a Swine Model of Diffuse Traumatic Brain Injury.Int J Mol Sci. 2025 Apr 9;26(8):3531. doi: 10.3390/ijms26083531. Int J Mol Sci. 2025. PMID: 40331981 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical